Annual Report to the Nation: Declines in lung cancer, melanoma death rates drive overall cancer mortality drop

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

From 2015 to 2018, the overall cancer death rate in the United States fell by 2.3% per year for men and 2.1% per year for women—an unprecedented drop, led by accelerated decline in deaths from lung cancer and melanoma.

By way of comparatison, the death rate for men dropped 1.8% per year from 2001-2015, and the death rate in women declined 1.4% per year from 2001-2015, according to this year’s Annual Report to the Nation, a study conducted by several federal agencies and cancer groups.

The report, published in JNCI: The Journal of the National Cancer Institute, also finds that overall cancer incidence rates continue to increase among females, children, adolescents and young adults. All trends in this report cover the period before the COVID-19 pandemic.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alexandria Carolan
Alexandria Carolan
Reporter

YOU MAY BE INTERESTED IN

Roy S. Herbst (middle) receives his award at the Innovation Gala of The Chemotherapy+ Foundation, with Robert Winn (left), director and Lipman Chair in Oncology at VCU Massey Comprehensive Cancer Center, and Katerina Politi (right), scientific director of YCC’s Center for Thoracic Cancers.Roy S. Herbst was awarded the Ezra Greenspan Award at the Innovation Gala of The Chemotherapy+ Foundation on Nov. 19 in New York City. 
FDA has approved FoundationOne Liquid CDx to be used as a companion diagnostic for Tepmetko (tepotinib) developed by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. Tepmetko received accelerated approval from FDA in February 2021 and traditional approval in February 2024 for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping alterations. FoundationOne Liquid CDx is the first FDA-approved companion diagnostic to identify patients who may be eligible for Tepmetko.
Alexandria Carolan
Alexandria Carolan
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login